⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5375204 | 0.80 | — | — | |
| SCHEMBL18207641 | 0.80 | — | — | |
| SCHEMBL15351587 | 0.80 | — | — | |
| SCHEMBL3751767 | 0.76 | SLC22A12 (0.41) | — | |
| SCHEMBL2642802 | 0.76 | L3MBTL1 (0.38) | — | |
| SCHEMBL2642604 | 0.74 | APOBEC3G (0.41) | — | |
| SCHEMBL14657961 | 0.74 | HTT (0.43) | — | |
| SCHEMBL2642333 | 0.74 | MCL1 (0.42) | — | |
| SCHEMBL4401750 | 0.74 | NFE2L2 (0.47) | — | |
| SCHEMBL2642229 | 0.72 | KMT2A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | claimed |
| US-20230142714-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2023-05-11 | — | — | US | claimed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | claimed |
| CN-115279763-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4025568-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| EP-4025574-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| EP-4025575-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2022-07-13 | — | — | EP | claimed |
| CN-114728918-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114728958-A | RIP1 inhibiting compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | claimed |
| EP-1399427-B1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LTD (GB) | 2004-11-03 | — | — | EP | claimed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | claimed |
| EP-1399427-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | Syngenta Limited (GB) | 2004-03-24 | — | — | EP | claimed |
| EP-1322616-A2 | QUINOLINE-(C=O)-(DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS INC. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | claimed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | claimed |
| WO-2002100837-A1 | PROCESS FOR THE PREPARATION OF AZOXYSTROBIN AND ANALOGUES THEREOF | SYNGENTA LIMITED (GB) | 2002-12-19 | — | — | WO | claimed |
| WO-2002018341-A9 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYST PROD INC (US) | 2002-11-21 | — | — | WO | claimed |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | MP BIOMEDICALS, LLC | 2002-05-02 | — | — | US | claimed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | claimed |